Analytical testing for biologics is evolving rapidly as new protocols become available and companies seek to expedite current methodologies. This article offers expert insight into bioassays and ...

BRANFORD, Conn.--(BUSINESS WIRE)--Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), a proteomics technology company redefining ...

How to use this book / David Wild -- Immunoassay for beginners / David Wild -- Immunoassay performance measures / Chris Davies -- Principles of competitive and immunometric assays (including ELISA) / ...

NT-proBNP is a cornerstone biomarker in the diagnosis and management of heart failure. Despite its widespread use, important biological and analytical challenges remain. One of the most sign ...

Single B-cell technologies have emerged as powerful screening tools to accelerate antibody discovery, offering R&D teams the potential to interrogate millions of individual antibody-secreting cells to ...

The development of new therapeutics targeting protein kinases is crucial in the fight against diseases like cancer. Kinase drug discovery programs rely on the precise characterization and screening of ...

Thought LeadersEdoardo FabiniPrincipal Scientist Evotec U.K. G-protein-coupled receptors (GPCRs) play a pivotal role in cellular signaling and have long been a major focus in drug discovery. These ...

A new article in the journal Nucleic Acid Therapeutics addresses the recognition by the U.S. Food and Drug Administration that immunogenicity assays may be necessary to measure immune responses to ...

Researchers at ESPCI Paris and Quantum-Si demonstrate scalable platform for parallel binding kinetics and sequencing in new preprint Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the ...